Advances in pharmaconenomic studies of duoxetacel
10.13699/j.cnki.1001-6821.2015.24.037
- VernacularTitle:多西他赛药物基因组学研究进展
- Author:
Ping WU
1
;
Su-Lan ZOU
;
Xue-Feng NI
Author Information
1. 苏州大学 医学院附属第三医院
- Keywords:
docetaxel;
pharmacogenomics;
gene polymorphism;
antitu-mor drug;
individualized treatment
- From:
The Chinese Journal of Clinical Pharmacology
2015;(24):2486-2488,2491
- CountryChina
- Language:Chinese
-
Abstract:
Docetaxel is widely used in the treatment of breast cancer, non -small cell lung cancer, prostate cancer and other cancer. However, individual differences in clinical efficacy and adverse drug reactions of docetaxel have attracted more and more attention in recent years.Domestic and foreign literatures have suggested that the genetic variation of drug metabolism related genes is one of the important reasons leading to individual differences. In this paper, correlations between genetic polymorphism of cytochrome P450 enzymes, multidrug resistance gene, drug transporters of docetaxel and individual difference of pharma-cokinetics/pharmacodynamics, clinical efficacy and adverse drug reactions of duoxetacel are reviewed.
